Reuters logo
BRIEF-Chromadex announces top-line results of its second human clinical trial
September 26, 2017 / 10:58 AM / in 3 months

BRIEF-Chromadex announces top-line results of its second human clinical trial

Sept 26 (Reuters) - Chromadex Corp:

* Chromadex announces top-line results of its second human clinical trial

* Chromadex Corp - ‍results from trial demonstrated that NR produced statistically significant increases in blood NAD+ compared to placebo​

* Chromadex Corp - ‍initial results of Niagen nicotinamide riboside chloride (NR) confirmed NR significantly raises co-enzyme NAD+ over 8-weeks

* Chromadex Corp - ‍study establishes effective dose range and validates safety for Niagen nicotinamide riboside chloride in 140 humans over an 8-week period​

* Chromadex Corp - ‍study confirms not only efficacy in raising NAD+, but also definitively documents safety of daily use of NR​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below